Vibha Sharma

With trial populations especially challenging to recruit in rare diseases, sponsors should focus on gathering more data from each patient. (Free access) Dose Optimization And Rare Diseases: Doing More With Less https://t.co/n4SnbEyzyU

The US FDA commissioner is putting sponsors on notice that the agency plans to screen for clinical trial fraud using AI technology. @dgingery (Free access) https://t.co/A1FopZFZYf

RT @scriplisatakagi: Japan has started to charge patients a portion of the difference between the reimbursement price of the generic and no…

RT @AmyJointSci: Exciting to see @ISRCTN’s new Transparency Tracker & Badges covered in @PharmaPinkSheet this week! https://t.co/rjAU3a4R…

Companies will still be able to use the International Reliance Procedure once the MHRA assumes full responsibility for prescription drug approvals in the UK at the beginning of 2025. @ScripIanS UK MHRA To Retain Multiple Approval Pathways From 2025 https://t.co/vVjTN7j7Yi

RT @EMA_News: 📢New pilot programme to support the development and assessment of orphan #MedicalDevices through freeadvice and guidance. O…

https://t.co/sWG8hlhvA2

RT @SarahKarlin: More companies developing treatments and vaccines for infectious diseases are seeing the value of incorporating human chal…

Japan’s PMDA has established its first overseas base in Bangkok https://t.co/9Kmm57NDZn

Swissmedic is reducing the fees for processing applications for non-commercially funded clinical trials by 80% as of 1 July 2024 @Swissmedic_ https://t.co/6LCnq0BB8k

Scrip analyzes data on the latest total compensation packages of the CEOs of the world’s leading #pharma companies, measuring them against company performance (Free access) Titans Of Pharma: J&J Back On Top For CEO Remuneration https://t.co/rJrHR8IUsu

RT @ICH_news: ICH is pleased to announce the publication of a press release following the meeting of the ICH Assembly in Fukuoka, Japan hel…

US FDA leadership has generally seemed apprehensive of going too hard on companies that don’t meet clinical trial diversity goals, but some industry insiders say a stronger FDA is needed to spark real change. (Free access) https://t.co/qNdf9xNQz1

A Job Well Done: AstraZeneca’s voluntary withdrawal of its COVID-19 vaccine is due to a surplus of other jabs targeting new variants, and not due to misinformation regarding very rare adverse events, reports @kevinatgrogan ($) https://t.co/hHfik5rGbJ

ICER's new Clinical trial Diversity Rating (CDR) framework provides an objective & transparent approach to evaluating trial diversity. The influential group's framework could impact US FDA's policy development in the area. (Free Access) https://t.co/Cha3hJS9JE

Forging partnerships with big pharma is more important than ever, and this article provides biotech leaders with insider pointers on how to approach this. (Free access) Pharma Happy To Be Custodian For Innovative Science From Cash-Strapped Biotechs https://t.co/6FfX15IPKZ

Australia is tightening its rules to ensure patients will have access to at least one IVD that is adequate for companion testing. (Free access) https://t.co/J75ff09jnu